Concepts (160)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sinusitis | 13 | 2023 | 158 | 4.440 |
Why?
|
| Rhinitis | 12 | 2023 | 141 | 3.860 |
Why?
|
| Paranasal Sinuses | 5 | 2022 | 61 | 1.670 |
Why?
|
| Nasal Polyps | 6 | 2023 | 53 | 1.370 |
Why?
|
| Immunosuppressive Agents | 2 | 2019 | 130 | 1.190 |
Why?
|
| Paranasal Sinus Neoplasms | 4 | 2022 | 61 | 1.160 |
Why?
|
| Endoscopy | 9 | 2023 | 154 | 1.020 |
Why?
|
| Chronic Disease | 11 | 2023 | 413 | 0.890 |
Why?
|
| Betacoronavirus | 5 | 2020 | 70 | 0.800 |
Why?
|
| Coronavirus Infections | 5 | 2020 | 80 | 0.760 |
Why?
|
| Pneumonia, Viral | 5 | 2020 | 84 | 0.760 |
Why?
|
| Skull Base Neoplasms | 1 | 2021 | 18 | 0.750 |
Why?
|
| Papilloma, Inverted | 1 | 2020 | 15 | 0.670 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2019 | 180 | 0.620 |
Why?
|
| Nasal Mucosa | 1 | 2018 | 12 | 0.610 |
Why?
|
| Neutrophils | 1 | 2018 | 89 | 0.590 |
Why?
|
| Otolaryngology | 4 | 2021 | 29 | 0.570 |
Why?
|
| Retrospective Studies | 17 | 2023 | 3283 | 0.560 |
Why?
|
| Invasive Fungal Infections | 1 | 2017 | 4 | 0.550 |
Why?
|
| Aspergillosis | 1 | 2017 | 8 | 0.550 |
Why?
|
| Mucormycosis | 1 | 2017 | 8 | 0.550 |
Why?
|
| Frozen Sections | 1 | 2017 | 11 | 0.550 |
Why?
|
| Humans | 34 | 2023 | 26260 | 0.550 |
Why?
|
| Nose Neoplasms | 3 | 2022 | 40 | 0.530 |
Why?
|
| Middle Aged | 15 | 2023 | 8541 | 0.400 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2021 | 27 | 0.370 |
Why?
|
| Adult | 11 | 2023 | 7516 | 0.360 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2020 | 25 | 0.340 |
Why?
|
| Simulation Training | 2 | 2020 | 40 | 0.330 |
Why?
|
| Nose | 2 | 2021 | 34 | 0.320 |
Why?
|
| Male | 14 | 2021 | 14168 | 0.300 |
Why?
|
| Female | 14 | 2021 | 14520 | 0.300 |
Why?
|
| Cerebrospinal Fluid Leak | 3 | 2023 | 20 | 0.290 |
Why?
|
| Internship and Residency | 2 | 2021 | 201 | 0.280 |
Why?
|
| Aged | 10 | 2023 | 8595 | 0.260 |
Why?
|
| Tertiary Care Centers | 3 | 2020 | 65 | 0.250 |
Why?
|
| Mometasone Furoate | 2 | 2022 | 8 | 0.240 |
Why?
|
| Skull Base | 2 | 2023 | 33 | 0.240 |
Why?
|
| Severity of Illness Index | 4 | 2021 | 853 | 0.240 |
Why?
|
| Inflammation | 3 | 2023 | 264 | 0.230 |
Why?
|
| Intracranial Hypertension | 1 | 2023 | 15 | 0.220 |
Why?
|
| Cerebrospinal Fluid Rhinorrhea | 1 | 2023 | 14 | 0.220 |
Why?
|
| Olfaction Disorders | 2 | 2021 | 47 | 0.210 |
Why?
|
| Diabetes Mellitus | 1 | 2023 | 127 | 0.190 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2021 | 49 | 0.190 |
Why?
|
| Surgical Flaps | 1 | 2021 | 45 | 0.190 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2021 | 79 | 0.190 |
Why?
|
| Pandemics | 5 | 2020 | 240 | 0.180 |
Why?
|
| Treatment Outcome | 4 | 2023 | 3285 | 0.180 |
Why?
|
| Air Pollutants | 1 | 2021 | 10 | 0.180 |
Why?
|
| Air Pollution | 1 | 2021 | 15 | 0.180 |
Why?
|
| Chemoradiotherapy | 1 | 2021 | 61 | 0.180 |
Why?
|
| Professional Role | 1 | 2021 | 36 | 0.180 |
Why?
|
| Natural Killer T-Cells | 1 | 2020 | 3 | 0.180 |
Why?
|
| Lymphoma, Extranodal NK-T-Cell | 1 | 2020 | 4 | 0.180 |
Why?
|
| Melanoma | 1 | 2021 | 57 | 0.180 |
Why?
|
| Child | 2 | 2022 | 1326 | 0.180 |
Why?
|
| Hemostatic Techniques | 1 | 2020 | 7 | 0.180 |
Why?
|
| Nasal Surgical Procedures | 2 | 2017 | 9 | 0.170 |
Why?
|
| Nasopharynx | 1 | 2020 | 4 | 0.170 |
Why?
|
| Epistaxis | 1 | 2020 | 9 | 0.170 |
Why?
|
| Otorhinolaryngologic Diseases | 1 | 2020 | 8 | 0.170 |
Why?
|
| Personnel, Hospital | 1 | 2020 | 16 | 0.170 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 1 | 2020 | 11 | 0.170 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 294 | 0.170 |
Why?
|
| Airway Management | 1 | 2020 | 15 | 0.170 |
Why?
|
| Urban Health Services | 1 | 2020 | 14 | 0.170 |
Why?
|
| Smell | 1 | 2020 | 17 | 0.170 |
Why?
|
| Tracheostomy | 1 | 2020 | 26 | 0.170 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 18 | 0.170 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2021 | 74 | 0.170 |
Why?
|
| Maxillary Sinus Neoplasms | 1 | 2020 | 7 | 0.170 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2020 | 5 | 0.170 |
Why?
|
| Point-of-Care Testing | 1 | 2020 | 29 | 0.170 |
Why?
|
| Sella Turcica | 1 | 2019 | 3 | 0.170 |
Why?
|
| Surgeons | 1 | 2021 | 84 | 0.170 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2022 | 675 | 0.170 |
Why?
|
| Head and Neck Neoplasms | 1 | 2021 | 148 | 0.170 |
Why?
|
| Surgical Wound | 1 | 2019 | 9 | 0.170 |
Why?
|
| Preoperative Care | 1 | 2020 | 120 | 0.160 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2019 | 29 | 0.160 |
Why?
|
| Carcinoma | 1 | 2020 | 65 | 0.160 |
Why?
|
| Disease Management | 1 | 2020 | 104 | 0.160 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2020 | 60 | 0.160 |
Why?
|
| Maxillary Diseases | 1 | 2018 | 4 | 0.160 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 343 | 0.150 |
Why?
|
| Fibrosis | 1 | 2018 | 27 | 0.150 |
Why?
|
| Phenotype | 1 | 2019 | 305 | 0.150 |
Why?
|
| Wound Healing | 1 | 2019 | 149 | 0.150 |
Why?
|
| Sleep Wake Disorders | 1 | 2020 | 121 | 0.150 |
Why?
|
| Telemedicine | 1 | 2020 | 104 | 0.150 |
Why?
|
| Clinical Competence | 1 | 2020 | 227 | 0.150 |
Why?
|
| Olfactory Nerve | 1 | 2017 | 2 | 0.140 |
Why?
|
| Olfactory Receptor Neurons | 1 | 2017 | 2 | 0.140 |
Why?
|
| Young Adult | 3 | 2020 | 1948 | 0.140 |
Why?
|
| Frontal Sinus | 1 | 2017 | 13 | 0.140 |
Why?
|
| Aspergillus | 1 | 2017 | 4 | 0.140 |
Why?
|
| Mucor | 1 | 2017 | 4 | 0.140 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 43 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2023 | 193 | 0.140 |
Why?
|
| Acute Disease | 1 | 2017 | 190 | 0.130 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 4594 | 0.130 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 473 | 0.120 |
Why?
|
| Postoperative Complications | 1 | 2021 | 825 | 0.120 |
Why?
|
| Decision Making | 1 | 2017 | 211 | 0.120 |
Why?
|
| Prognosis | 3 | 2021 | 710 | 0.120 |
Why?
|
| Prospective Studies | 3 | 2021 | 1665 | 0.100 |
Why?
|
| Immunotherapy | 2 | 2021 | 55 | 0.090 |
Why?
|
| Survival Analysis | 2 | 2021 | 242 | 0.090 |
Why?
|
| Databases, Factual | 2 | 2021 | 315 | 0.080 |
Why?
|
| Neoplasm Staging | 2 | 2021 | 358 | 0.080 |
Why?
|
| Survival Rate | 2 | 2020 | 315 | 0.080 |
Why?
|
| Chicago | 2 | 2020 | 857 | 0.070 |
Why?
|
| Risk Factors | 2 | 2021 | 2221 | 0.060 |
Why?
|
| Adolescent | 2 | 2020 | 2172 | 0.060 |
Why?
|
| Encephalocele | 1 | 2023 | 24 | 0.050 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2022 | 34 | 0.050 |
Why?
|
| Eosinophils | 1 | 2022 | 38 | 0.050 |
Why?
|
| Nasal Lavage | 1 | 2021 | 4 | 0.050 |
Why?
|
| Pituitary-Adrenal System | 1 | 2021 | 12 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2023 | 567 | 0.050 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2021 | 22 | 0.050 |
Why?
|
| Tourette Syndrome | 1 | 2021 | 13 | 0.050 |
Why?
|
| Hydrocortisone | 1 | 2021 | 38 | 0.050 |
Why?
|
| Taste Disorders | 1 | 2021 | 4 | 0.050 |
Why?
|
| Hospitals, Teaching | 1 | 2021 | 29 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2021 | 160 | 0.050 |
Why?
|
| Environmental Exposure | 1 | 2021 | 14 | 0.050 |
Why?
|
| Particulate Matter | 1 | 2021 | 19 | 0.040 |
Why?
|
| Observer Variation | 1 | 2021 | 96 | 0.040 |
Why?
|
| Surgery Department, Hospital | 1 | 2020 | 4 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 321 | 0.040 |
Why?
|
| Logistic Models | 1 | 2021 | 353 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 2020 | 47 | 0.040 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 18 | 0.040 |
Why?
|
| Education, Nursing, Continuing | 1 | 2020 | 19 | 0.040 |
Why?
|
| Inservice Training | 1 | 2020 | 26 | 0.040 |
Why?
|
| Nasal Cavity | 1 | 2020 | 32 | 0.040 |
Why?
|
| Induction Chemotherapy | 1 | 2020 | 13 | 0.040 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 40 | 0.040 |
Why?
|
| Global Health | 1 | 2020 | 37 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2020 | 55 | 0.040 |
Why?
|
| Perception | 1 | 2020 | 75 | 0.040 |
Why?
|
| Emergencies | 1 | 2020 | 34 | 0.040 |
Why?
|
| Genomics | 1 | 2020 | 57 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2020 | 47 | 0.040 |
Why?
|
| Margins of Excision | 1 | 2020 | 30 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2021 | 178 | 0.040 |
Why?
|
| Patient Selection | 1 | 2020 | 184 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 279 | 0.040 |
Why?
|
| Prevalence | 1 | 2020 | 441 | 0.040 |
Why?
|
| Mass Screening | 1 | 2020 | 174 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 683 | 0.040 |
Why?
|
| Smoking | 1 | 2019 | 164 | 0.040 |
Why?
|
| Eosinophilia | 1 | 2018 | 35 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 314 | 0.040 |
Why?
|
| Age Factors | 1 | 2020 | 744 | 0.040 |
Why?
|
| Time Factors | 1 | 2021 | 1347 | 0.030 |
Why?
|
| Cadaver | 1 | 2017 | 363 | 0.030 |
Why?
|
| United States | 1 | 2020 | 2043 | 0.030 |
Why?
|
Papagiannopoulos's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(160)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(21)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_